Drug intelligence / Profile preview

Prodencel

Development stage: Phase 1
Lead developer: Shanghai Huidun Bio-Technology
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

Prodencel is an autologous dendritic cell vaccine developed as a therapeutic cancer vaccine targeting prostate cancer-specific antigens. It is designed to stimulate the patient's immune system to recognize and attack prostate cancer cells. The product uses the patient’s own dendritic cells that are exposed ex vivo to prostate cancer antigens and then re-administered as a personalized immunotherapy. Prodencel is being investigated for use in metastatic castration-resistant prostate cancer and has reached Phase 1 clinical trials in China[1][2][3].

Other names: prodencelPuledengsaiAutologous dendritic cell tumor vaccine (Shangai Humantech Biotechnology)前列腺癌治疗性疫苗(惠盾生物)

Beyond the preview

Go deeper on Prodencel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prodencel.

Explore the full profile